Drug Details
| General Information of the Drug (ID: DR1277) | ||||
|---|---|---|---|---|
| Name |
Diethylcarbamazine
|
|||
| Synonyms |
diethylcarbamazine; 90-89-1; N,N-diethyl-4-methylpiperazine-1-carboxamide; Carbamazine; Diethyl carbamazine; Carbilazine; Ethodryl; Notezine; Bitirazine; Caricide; Cypip; Ditrazine Base; Caracide; Spatonin; 1-Piperazinecarboxamide, N,N-diethyl-4-methyl-; N,N-Diethyl-4-methyl-1-piperazinecarboxamide; N,N-Diethylcarbamazine; UNII-V867Q8X3ZD; RP 3799; 84L; CHEBI:4527; V867Q8X3ZD; Bitirazine; Caracide;Carbamazine; MMV002816; Diaethylcarbamazinum; Dietilcarbamazina; Diethylcarbamazinum; Diethylcarbamazine [INN:BAN]; Diethylcarbamazinum [INN-Latin]; Dietilcarbamazina [INN-Spanish]; NSC1364; N,N-diethyl(4-methylpiperazinyl)carboxamide; Camin (TN); Diethylcarbamazine (INN); EINECS 202-023-3; 1-Diethylcarbamoyl-4-Methylpiperazine; BRN 0143029; AI3-19612; 1-Diethylcarbamyl-4-methylpiperazine; 1-Methyl-4-diethylcarbamoylpiperazine; Banocide (Salt/Mix); Caritrol (Salt/Mix); Nemacide (Salt/Mix); Spectrum_000938; NN-Diethyl-4-methyl-1-piperazinecarboxamide; Prestwick0_000284; Prestwick1_000284; Prestwick2_000284; Prestwick3_000284; Spectrum2_001022; Spectrum3_000390; Spectrum4_000511; Spectrum5_000877; diethyl carbamazine citrate; CHEMBL684; EC 202-023-3; SCHEMBL67289; BSPBio_000188; BSPBio_002179; KBioGR_001081; KBioSS_001418; 4-23-00-00225 (Beilstein Handbook Reference); DivK1c_000548; SPBio_001203; SPBio_002407; BPBio1_000208; ZINC1288; DTXSID1022928; KBio1_000548; KBio2_001418; KBio2_003986; KBio2_006554; KBio3_001399; NINDS_000548; HMS3604F12; 1-Diethylcarbamoyl-4-methylpiperzine; MFCD00023288; SBB008185; AKOS003268016; DB00711; DS-9360; MCULE-7296820622; NE55264; IDI1_000548; NCGC00178778-01; NCGC00178778-02; NCGC00178778-07; AK158485; ST094965; SBI-0051345.P003; DB-080764; R.P. 3799; 1-(N,N-Diethylcarbamoyl)-4-methylpiperazine; AB00053457; FT-0624832; C07968; D07825; N,N-diethyl-4-methyl-piperazine-1-carboxamide; AB00053457_12; Q409267; BRD-K45542189-048-05-6; BRD-K45542189-048-15-5
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Filariasis [ICD-11: 1F66] | Approved | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| ADMET Property |
Absorption
The drug is rapidly absorbed following oral administration
Elimination
35% of drug is excreted from urine in the unchanged form
Half-life
The concentration or amount of drug in body reduced by one-half in 8 hours
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 30.10562 micromolar/kg/day
Water Solubility
The ability of drug to dissolve in water is measured as 63.7 mg/mL
Click to Show/Hide
|
|||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C10H21N3O
|
|||
| PubChem CID | ||||
| Canonical SMILES |
CCN(CC)C(=O)N1CCN(CC1)C
|
|||
| InChI |
1S/C10H21N3O/c1-4-12(5-2)10(14)13-8-6-11(3)7-9-13/h4-9H2,1-3H3
|
|||
| InChIKey |
RCKMWOKWVGPNJF-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 90-89-1
|
|||
| ChEBI ID | ||||
| TTD Drug ID | ||||
| DrugBank ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Hesperidin | Citrus sinensis | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | GGT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | GPT | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | GPT | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | IL19 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | IL6 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | TGFB1 | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | Adult male wistar rats (250-275 g) were used in this study. | |||||
| Experimental
Result(s) |
DEC when combined with HDN blunted EtOH-induced necroinflammation and elevation of liver injury parameters in serum. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Arachidonate 5-lipoxygenase (5-LOX) | Molecule Info | [3] | |
| BioCyc | Aspirin-triggered lipoxin biosynthesis | Click to Show/Hide | ||
| 2 | Resolvin D biosynthesis | |||
| 3 | Leukotriene biosynthesis | |||
| 4 | Lipoxin biosynthesis | |||
| 5 | Aspirin triggered resolvin D biosynthesis | |||
| 6 | Aspirin triggered resolvin E biosynthesis | |||
| KEGG Pathway | Arachidonic acid metabolism | Click to Show/Hide | ||
| 2 | Metabolic pathways | |||
| 3 | Serotonergic synapse | |||
| 4 | Ovarian steroidogenesis | |||
| 5 | Toxoplasmosis | |||
| NetPath Pathway | IL4 Signaling Pathway | Click to Show/Hide | ||
| Pathwhiz Pathway | Arachidonic Acid Metabolism | Click to Show/Hide | ||
| WikiPathways | Vitamin D Receptor Pathway | Click to Show/Hide | ||
| 2 | Arachidonic acid metabolism | |||
| 3 | Eicosanoid Synthesis | |||
| 4 | Selenium Micronutrient Network | |||
